Versant Ventures — Full Portfolio

Century Therapeutics develops allogeneic, iPSC-derived cell therapies using gene editing and protein engineering for autoimmune diseases including type 1 diabetes and cancer.

AI & Machine LearningBiotechHealthtechMedical DevicesPhiladelphia, US

Osvaldo Flores, Ph.D.(Executive Officer, Director)Douglas Carr(Executive Officer)inBPBrent Pfeiffenberger(President and Chief Executive Officer)inGregory Russotti(Chief Technology and Manufacturing Officer)CCChad Cowan(Chief Scientific Officer)in

BoardToshikazu Ban(Director)

Board seatCRCarlo Rizzuto· per SEC Form D

Co-investorsLILifeSci Venture PartnersRARA CapitalCACasdin Capital

Black Diamond Therapeutics develops small-molecule kinase inhibitors targeting families of oncogenic mutations across cancer types, including its lead candidate silevertinib for EGFR-mutant lung cancer and glioblastoma.

EBElizabeth Buck(Chief Scientific Officer)inBrent Hatzis-Schoch(Chief Operating Officer and General Counsel)inSYSergey Yurasov(Chief Medical Officer)inMelanie Morrison(Chief Development Officer)

Co-investorsLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)NENextech InvestNSNSG VenturesRARA Capital+4 more

Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.

BiotechMedical DevicesLa Jolla, US

ZDZachary D. Hornby(Executive Officer, Director)inRDRobert Doebele(Chief Medical Officer)inChristian Hassig(Chief Scientific Officer)JOJessica Oien(Chief Legal Officer and Corporate Secretary)in

BoardBenjamin Cravatt, Ph.D.(Director)KBKristina Burow(Director)in

Co-investorsARARCH Venture PartnersNENextech InvestRARA CapitalWEWellington ManagementALAlexandriaCICity Hill Ventures+3 more

Contineum is a biopharmaceutical company developing small molecule drug candidates to treat inflammatory and fibrotic diseases by modulating critical disease pathways.

BiotechHealthtech

CSCarmine Stengone(President and Chief Executive Officer)inPTPeter T. Slover(Chief Financial Officer)inDSDaniel S. Lorrain(Chief Scientific Officer)inTimothy R. Watkins(Chief Medical Officer and Head of Development)in

Co-investorsHAHadean VenturesRERed Tree VentureSASamsara BioCapitalCACasdin CapitalFRFranklin TempletonJJJJDC+1 more

Late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision.

BiotechSouth San Francisco, US

Josh Lehrer(Executive Officer, Director)KSKatherine Stultz(Executive Officer)inPhilip Gutry(Executive Officer)Evert Schimmelpennink(Chief Executive Officer, President, Secretary, and Director)Daniel Chevallard(Chief Financial Officer)Shawn Olsson(Chief Commercial Officer)in

Co-investorsSASamsara BioCapital

Passage Bio is a biotechnology company developing treatments for central nervous system (CNS) diseases, with a focus on neurodegenerative conditions.

BiotechHealthtechPhiladelphia, US

WCWilliam Chou(Chief Executive Officer)Tadataka Yamada(Executive Officer, Director, Promoter)SSStephen Squinto(Executive Officer, Director)in

BoardPHPatrick Heron(Director)inCGCarl Gordon(Director)inThomas Street Address 1 Woiwode(Director)

Co-investorsFRFrazier Life SciencesACAccess BiotechnologyFRFrazier Healthcare PartnersLILilly Asia VenturesNENew Leaf Venture PartnersOROrbiMed+2 more

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

VPVijaya Pattabiraman(Co-founder & Chief Technology Officer)inJBJeffrey Bode(Scientific co-founder)inFWFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Board seatTWTom WoiwodeAMAlex Mayweg· per SEC Form D

Co-investorsRARA CapitalJOJohnson & Johnson Innovation – JJDCVEVenrockALAlexandriaBLBlackRockFIFidelity Investments+2 more

Lycia Therapeutics is a biotechnology company developing LYTAC (Lysosomal Targeting Chimera) therapeutics that bind disease-causing extracellular and cell-surface proteins and route them into the cell's lysosome for degradation.

BiotechHealthtechSouth San Francisco, US

CBCarolyn Bertozzi(Lycia founder and Professor of Chemistry, Stanford University)inAWAetna Wun Trombley(President and CEO)inABAmy Bachrodt(Chief Financial Officer)inCLChin Lee(Chief Medical Officer)inSSSteve Staben(Chief Scientific Officer)inSTSofia Touami(Chief Business Officer)in

Board seatCOClare Ozawa· per SEC Form D

Co-investorsREREDMILEHBHBM Healthcare InvestmentsHBHBM PartnersBABAM ElevateFRFranklin TempletonINInvus+5 more

AllRock Bio is a drug development company advancing novel therapies for pulmonary hypertension, interstitial lung diseases, and other fibrotic conditions.

BiotechNatick, US

CPCatherine Pearce(CEO & Founder)inDHSc(Founder)JRJustin R Thompson(Founder)in

Co-investorsWEWestlake BioPartnersWEWestlake Village BioPartners

Capsida Biotherapeutics develops engineered gene therapies for rare and common neurological and ocular diseases using an AAV capsid platform that enables improved brain and retinal delivery compared to naturally occurring capsids.

BiotechDeep TechDigital HealthMedical Devices

Viviana GradinaruNick Goeden, Ph.D.(Co-founder)NFNicholas Flytzanis(Co-founder)in

Co-investorsWEWestlake Village BioPartners

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Greg Lazar, Ph.D.(Co-Founder and Chief Scientific Officer)FHForbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGLGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)KDKarim Dabbagh(Chief Executive Officer, Board Member)in

BoardALAlicia Levey(Director)

Co-investorsQIQiming Venture PartnersSVSV Health InvestorsALAlexandriaDEDementia Discovery FundQIQiming HealthcareQIQiming Venture Partners USA

Fable Therapeutics is a biotech company using protein engineering to develop biologics targeting the activin receptor type II (ActR2) pathway for obesity and related metabolic diseases.

BiotechHealthtechLongevity

GMGeoff MacKay(President & CEO)David Baker(Chief Scientific Officer)Rhonda Wideman(Chief Business Officer)Zack McNealy(Chief Financial Officer)

Co-investorsMPMPM BioImpactDCDCVC BioLILilly Asia VenturesDCDCVC (Data Collective)

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical DevicesBrisbane, US

JMJordi Mata-Fink(Chief Executive Officer, Co-Founder)inRTRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)inJordi Mata-Fink, Ph.D.(Chief Executive Officer, Co-Founder)Raman Talwar, M.S.(Chief Technology Officer, Co-Founder)Pat Sharp, Ph.D.(Scientific Founder)

Co-investorsFOForbionANAndreessen HorowitzARARCH Venture PartnersFEFelicis VenturesGVGV (Google Ventures)

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

PLPatrick Loustau(President and Chief Executive Officer)in

Co-investorsNONovartis Venture FundSASanofi VenturesFOForbion

iECURE is a clinical-stage biotechnology company developing in vivo genome editing therapies that insert a functional copy of a gene into a patient's genome to treat rare, life-threatening genetic diseases in children.

BiotechHealthtechMedical Devices

JMJames M. Wilson(Scientific Founder)JTJoseph Truitt(CEO & Board Member)inPFPaul Firuta(COO)inAMAlex Monteith(Chief Business Officer)David Garrett(CFO)inGMGabriel M. Cohn(Chief Medical Officer)in

Co-investorsOROrbiMedLYLYFE Capital

Light Horse Therapeutics is a drug discovery company applying scientific expertise and innovation to advance healthcare through collaborative development.

AI & Machine LearningBiotechMedical Devices

Co-investorsTATaiho Ventures, LLCABAbbVieMUMubadala Capital

Nested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology.

AI & Machine LearningBiotechHealthtech

ADArvin Dar(Co-founder & Board Observer)inKevan Shokat(Scientific Co-founder)KHKlaus Hoeflich(Co-founder & former Chief Scientific Officer)inDMDarrin Miles(Chief Executive Officer)inPKPhilip Komarnitsky(Chief Medical Officer)inTanja Weber(Chief Business Officer)in

Co-investorsFOForesite CapitalSISixty Degree CapitalCOCowen Healthcare InvestmentsGOGoldman SachsSESection 32

Nexotx is a drug discovery company that identifies and develops medicines targeting previously undrugged biological pathways using chemical biology approaches.

AI & Machine LearningBiotechDeep Tech

APAndrew Phillips(Founder)John Athanosopoulos(Founder)MKMichael Kim(Founder)inRhamy Zeid(Founder)

Co-investorsNENew Enterprise Associates (NEA)

Nouscom is a biotech company whose investors page lists its venture capital backers.

BiotechHealthtech

Riccardo Cortese(Co-Founder)Marina Udier(Chief Executive Officer and Board Director)Elisa Scarselli(Chief Scientific Officer and Co-Founder)Alfredo Nicosia(Co-founder)Antonella Folgori(Co-founder)Stefano Colloca(Co-founder)

Co-investors5A5AM VenturesANAndera PartnersANAngelini VenturesRERevelation PartnersXGXGEN VentureBPBpifrance+6 more

RedRidge Bio discovers and develops biparatopic antibodies (antibodies that bind two sites on a single protein), including biparatopic antibody-drug conjugates, as therapeutics for oncology and autoimmune diseases.

BiotechHealthtech

Bill Sellers(Scientific Founder and Director Cancer Program, Broad Institute)Stephen Yoder(President & CEO)in

Co-investorsNENew Enterprise Associates (NEA)SISixty Degree CapitalIDIDG Capital

Santa Ana Bio is a biotech company developing engineered antibody therapeutics that target the immune pathways and cells driving autoimmune and inflammatory diseases.

AI & Machine LearningBiotechHealthtechMedical DevicesAlameda, US

PEPeter Emtage(Founder & CEO)inAlexander Rudensky(Scientific Founder)Richard Flavell(Scientific Founder)GLGraham Lord(Scientific Founder)inASAnsuman Satpathy(Scientific Founder)inNYNewman Yeilding(Chief Medical Officer)in

Co-investorsACAccess BiotechnologyANAndreessen HorowitzGVGV (Google Ventures)RTRTW Investments L.P.TPTPGACAccess Industries+1 more

Soteria Biotherapeutics develops protein-based biotherapeutics and small molecules using its LITE Switch technology platform for drug discovery and development across oncology, immune-oncology, and inflammatory disease indications.

BiotechDeep TechHealthtechMedical DevicesWellness & FitnessSan Francisco, US

Jim Wells(Co-founder, Scientific Advisory Board Chair)KMKristine M Ball(Executive Officer, Director)inZHZachary Hill(Executive Officer, Director)in

BoardNisha Marathe(Director)DADavid Allison(Director)inKGKeno Gutierrez(Director)in

Co-investors5A5AM VenturesNONovartis Venture FundRORoche Venture FundBIBioGeneration VenturesWEWestlake Village BioPartners

T-knife Therapeutics is a biopharmaceutical company developing T cell therapies to treat cancer, with an initial focus on solid tumors.

BiotechHealthtechBerlin, DE

EKElisa Kieback(Co-founder & Chief Technology Officer)inTBThomas Blankenstein(Scientific Founder)TSThomas Soloway(Chief Executive Officer)CLCamille Landis(Chief Business Officer / Chief Financial Officer)inPeggy Sotiropoulou(Chief Scientific Officer)in

Co-investorsANAndera PartnersEQEQT Life SciencesRARA CapitalSISixty Degree CapitalFIFidelity Investments

Tentarix Biotherapeutics develops multifunctional biologics to modernize healthcare standards through precision medicine.

BiotechDeep TechHealthtechMedical Devices

BoardSASrini Akkaraju(Director, Founder)inPaul Kang(Director, Founder)

Co-investorsSASamsara BioCapitalGIGilead Sciences

858 Therapeutics is a clinical-stage biotechnology company developing targeted cancer therapies that act on tumor dependencies in DNA damage response (DDR) pathways.

BiotechHealthtechSan Diego, US

SJStafford Jeffrey(Executive Officer, Director)inJVJames Veal(Executive Officer)Katherine Bell-McGuinn(Executive Officer)Joseph Leveque(Chief Medical Officer)

BoardABAli Behbahani(Director)in

Board seatCOClare OzawaMMMonal MehtaCRCarlo Rizzuto· per SEC Form D

Co-investorsNENew Enterprise Associates (NEA)VEVersant Venture Capital

Enable Injections develops and manufactures enFuse, a wearable drug delivery device that delivers large volumes of pharmaceutical and biologic therapeutics subcutaneously for patients with chronic diseases.

BiotechHealthtechMedical DevicesCincinnati, US

MHMike Hooven(Chairman, President and CEO)inTimothy Flaherty(Executive Officer)Simone Song(Director)Karen Robards(Director)Richard J D'Augustine(Director)Norman R. Weldon(Director)

Board seatBRBeckie Robertson· per SEC Form D · $30M raise · filed Jan 2026

Co-investorsANAngel Physicians FundCICincyTechLILightship CapitalOHOhio Innovation FundMAMagnetar AI Ventures

Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins.

AI & Machine LearningBiotechDeep TechAustin, US

Joanne Dove Kotz(Founder)inJoel Barrish(Chief Scientific Officer)Donald W. Nicholson(Director)Matthew Hammond(Director)Caroline Stark Beer(Chief Business Officer)Carlo Rizzuto(Director)

Board seatCRCarlo Rizzuto· per SEC Form D

Co-investorsAVAvalon BioVenturesBABain Capital Life SciencesPFPfizer Venture InvestmentsRARA CapitalPFPfizer VenturesPOPolaris Partners

Developing biologic therapies for autoimmune disorders; acquired by Merck for $1.85B in 2021.

BiotechCambridge, US

JVJo Viney(Executive Officer)RKRahul Kakkar(Executive Officer, Director)inACAnthony Coyle(Executive Officer, Director)inChristopher Fuglesang(Director)Donald Frail(Director)Daniel Becker(Director)

Board seatCRCarlo Rizzuto· per SEC Form D · $80M raise · filed Apr 2020

Co-investorsACAccess BiotechnologyJDJDRF T1D FundMIMission BiocapitalRARA CapitalSRSR One Capital ManagementPOPolaris Partners

BiotechNew York, US

MBMichael Burgess(Executive Officer)Jose Manuel Otero(Executive Officer)Robert Gould(Director)inJHJane Henderson(Executive Officer)inStefan Larson(Director)Patrick Machado(Director)

Board seatBBBrad BolzonJDJerel Davis· per SEC Form D

Co-investorsBRBrace PharmaF-F-Prime CapitalFAFACIT (Fight Against Cancer Innovation Trust)FOFoothill VenturesVEVenture OntarioOROrbiMed+1 more

Developing ceftibuten-ledaborbactam etzadroxil, a clinical phase 3-ready oral beta-lactam/beta-lactamase inhibitor combination for complicated urinary tract infections.

BiotechMalvern, US

Christopher J. Burns(Executive Officer, Director)Daniel C. Pevear(Executive Officer)Michael Diem(Director)Vincent J. Milano(Director)Ezra Felker(Executive Officer)Shelley Chu(Director)

Board seatCRCarlo Rizzuto· per SEC Form D · $47.1M raise · filed Nov 2018

Co-investorsAMAMR Action FundBIBioAdvanceFOForesite Capital

Ventus discovers and develops small-molecule medicines using its proprietary ReSOLVE platform, focused on structure-based drug discovery.

AI & Machine LearningBiotechDeep TechHealthtechWaltham, US

Judith Lieberman(Co-Founder)DKDaniel Koerwer(Executive Officer)inMCMichael Crackower(Executive Officer)inZachary McNealy(Executive Officer)Marcelo Bigal, M.D., Ph.D.(President and Chief Executive Officer)

BoardJRJosh Resnick(Director)in

Board seatMWMarkus WarmuthJDJerel Davis· per SEC Form D

Co-investorsANAndreessen HorowitzGVGV (Google Ventures)RARA CapitalSOSoftBank Vision FundALAlexandriaBIBiotechnology Value Fund+3 more

BiotechIrvine, US

Alan Waterhouse(President and Chief Operating Officer)Jason Tester(Chief Financial Officer and Secretary)James V. Mazzo(President, Chief Executive Officer and Chairman of the Board)

BoardArjun Arora(Director)Richard L. Lindstrom, M.D.(Director)William J. Link(Director)

Co-investorsEVEvidity Health CapitalFLFlying L PartnersRERevelation PartnersWEWestern Technology InvestmentHEHEALTHCARE ROYALTY PARTNERSSVSV Life Sciences+1 more

HealthtechSt Louis, US

Andrea M. Clegg(Executive Officer)Louis Silverman(Executive Officer, Director)

BoardBLBarbara Lubash(Director)inMichael Mikolajczyk(Director)TBTimothy B. Petersen(Director)inDavid N. Schopp(Director)

Co-investorsARArboretum Ventures

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureFOForesite CapitalFRFrazier Life SciencesGEGeneral AtlanticLILifeSci Venture PartnersSCScion Life Sciences+2 more

AlterG develops anti-gravity treadmill systems using patented Differential Air Pressure technology to enable rehabilitation and athletic training.

HardwareHealthtechMedical DevicesSports TechFremont, US

Ross Jaffe(Director)Charles Remsberg(Executive Officer, Director)Antonio Mora(Director)David Grenewetzki(Director)Kevin Davidge(Executive Officer)Mark McKee(Director)

Co-investorsMPMPM BioImpactVIVivo Capital

Antag Therapeutics develops GIP receptor antagonist therapies for obesity, diabetes, and overweight patients.

BiotechHealthtechCopenhagen, DK

JJJens Juul Holst(Founder)MRMette Rosenkilde(Founder)in

Co-investorsBRBroadview VenturesNONovo HoldingsSRSR One Capital Management

Aprea Therapeutics is a biopharmaceutical company developing novel cancer therapies targeting DNA damage response pathways to treat solid tumors including ovarian, colorectal, prostate, and breast cancers.

BiotechDigital HealthMedical DevicesDoylestown, US

JPJohn P. Hamill(Executive Officer)inOGOren Gilad(Chief Executive Officer, President)in

BoardJean-Pierre Bizzari(Director)Gabriela Gruia(Director)Rifat Pamukcu(Director)Bernd Seizinger(Director)

Co-investors5A5AM VenturesHEHealthCapRORobin Hood VenturesRORosetta Capital Ltd.SOSoleus Capital

Baseline is a biotech company focused on metabolism, obesity, incretins, and GLP-1-based strategies for substance use disorders, drawing on drug development and addiction medicine expertise.

BiotechDigital HealthHealthtech

Co-investorsVEVery Serious Ventures

Belharra Therapeutics develops small molecule therapies aimed at previously undruggable protein targets across the proteome.

BiotechDeep Tech

Blue Rock Therapeutics discovers and develops cell therapies to treat disease and improve patient outcomes.

AI & Machine LearningBiotechHealthtechMedical DevicesCambridge, US

Borealis develops RNA medicines to treat kidney diseases.

BiotechDigital Health

Co-investorsWEWestlake Village BioPartners

Cimeio Therapeutics develops paired immunotherapies and gene-editing-based cell shielding technology that deplete diseased cells while protecting healthy hematopoietic stem cells from the same treatment.

BiotechDeep TechHealthtechBasel, CH

CRISPR Therapeutics is a biotechnology company developing gene-based medicines using CRISPR/Cas9 gene-editing technology.

BiotechDeep TechHealthtechZug, CH

Emmanuelle Charpentier(Founder)SKSamarth Kulkarni(Chief Executive Officer and Chairman of the Board)inJRJames R. Kasinger(General Counsel and Secretary)inSKStephen Kennedy(Head of Technical Operations)inMWMegan Wherry Menner(Head of Human Resources)inNPNaimish Patel(Chief Medical Officer)in

Co-investorsAVAvoro Capital AdvisorsCLCLI VenturesKHKhosla VenturesNENew Enterprise Associates (NEA)SRSR One Capital ManagementWEWellington Management+2 more

Enterprise Therapeutics is a drug discovery company developing therapies for respiratory diseases such as cystic fibrosis, asthma, and COPD.

BiotechHealthtechBrighton, GB

JFJohn Ford(Co-founder)inMGMartin Gosling(Founder)in

Co-investorsEPEpidarex CapitalNONovartis Venture FundFOForbionIPIP GroupPAPanakes Partners

Medtronic designs and develops medical technology for treating complex diseases.

AI & Machine LearningDigital HealthHealthtechMedical Devices

Co-investors8V8VCCWCWRU Technology VenturesELElevate VenturesMEMenlo VenturesOAOak Investment PartnersPFPfizer Venture Investments+5 more

Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.

Co-investorsLALatterell Venture PartnersMPMPM BioImpactOROrbiMedTHThe Vertical Group

Nexoplex Bio develops immunotherapies designed to target tumors through recognition of HLA-peptide complexes using multi-specific antibodies, aimed at cancers including certain lung, gastric, esophageal, head and neck, and cervical cancers.

BiotechHealthtechSan Carlos, US

AAAndrew Allen(Executive Officer, Director)inVassiliki Economides(Executive Officer)MHMatthew Hawryluk(Executive Officer)inWayne(CEO)Rachel(VP of Operations)Shefali Agarwal(Director)

Co-investorsFRFrazier Life SciencesGVGV (Google Ventures)SOSofinnova VenturesTHThe Column GroupREREDMILE

Nexoplex Bio develops immunotherapies that target tumor cells through recognition of HLA-peptide complexes using multi-specific antibodies, addressing tumor types including lung, gastric, esophageal, head and neck, cervical cancers, and lung squamous cell carcinoma.

BiotechDeep TechHealthtechSan Carlos, US

Wayne(CEO)Rachel(VP of Operations)

Co-investorsBABay City CapitalGVGV (Google Ventures)LALAVLILilly Asia VenturesALAlexandriaFRFrazier Healthcare Partners+1 more

Helicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone.

BiotechHealthtechSouthbury, US

KRKevin Russ(Chief Executive Officer)inPDPeter DiLaura(Chief Executive Officer and Board Director)inWaters Kellogg(Director)Lucas B. Turner(Director)Joshua Dotson(Director)Holger Koehler(Director)

Co-investorsLOLongitude CapitalOROrbiMedWEWellington Management

Immunotherapy oncology company engineering technologies to activate the immune system; acquired by Merck in February 2019 for $0.3B.

BiotechHealthtechMedical DevicesSeattle, US

DBDavid Baltimore(Director)Carlos V. Paya(Executive Officer, Director)Stephen R. Brady(Executive Officer)inJHJan Henrik ter Meulen(Executive Officer)Paul Rickey(Executive Officer)inWayne Gombotz(Executive Officer)in

Co-investorsAIAisling CapitalATAtlas VentureHMHM Venture PartnersOUOUP (Osage University Partners)SASanderling VenturesSASanofi Ventures+4 more

Inari Medical develops mechanical thrombectomy devices for treating venous thromboembolism conditions, including pulmonary embolism, deep vein thrombosis, in-stent thrombosis, and arteriovenous fistula thrombosis.

HardwareHealthtechMedical DevicesIrvine, US

WHWilliam H. Hoffman(Executive Officer, Director)inRobert Rosenbluth(Executive Officer, Director)

BoardDonald Milder(Director)KNKirk Nielsen(Director)inJRJonathan Root(Director)inBrian Cox(Director)

Co-investorsGIGilde HealthcareUSUS Venture PartnersVEVensana Capital

BiotechSan Diego, US

JSJeffrey Stafford, Ph.D.(Executive Officer, Director)James Veal, Ph.D.(Executive Officer)Ariel Feldstein, M.D.(Director)

BoardBradley Bolzon, Ph.D.(Director)Thomas Woiwode, Ph.D.(Director)

BiotechSan Diego, US

Kevin Forrest, Ph.D.(Executive Officer, Director)

BoardClare Ozawa, Ph.D.(Director)Beth Seidenberg, M.D.(Director)

Co-investorsOUOUP (Osage University Partners)WEWestlake Village BioPartnersKLKleiner Perkins

LENZ Therapeutics is a pharmaceutical company developing and commercializing VIZZ™, an FDA-approved aceclidine-based eye drop for treating presbyopia, a vision condition affecting over 128 million people in the US.

BiotechHealthtechMedical DevicesSan Diego, US

JMJames McCollum(Co-founder, Board Member)ESEef SchimmelpenninkinESEvert Schimmelpennink(President and CEO)

Co-investorsALAlpha Wave GlobalRARA CapitalRARaptor GroupRTRTW Investments L.P.SESectoral Asset Management

Metavention is developing a treatment that targets the sympathetic nervous system to disrupt overactive nerves believed to contribute to high blood pressure and other metabolic diseases.

BiotechHealthtechMedical DevicesEden Prairie, US

Bobak Azamian(Executive Officer, Director)Tony Vrba(Executive Officer)Kevin Hykes(Executive Officer, Director)KNKirk Nielsen(Director)in

Co-investorsSASanderling VenturesNENew Enterprise Associates (NEA)VEVensana Capital

Van Nuys, US

EMEric Miller(Executive Officer, Director)inMichael Lockard(Executive Officer)in

BoardWarren Packard(Director)Kevin Wasserstein(Director)Eugene Chen(Director)Michael Sweeney(Director)

Co-investorsCHChevron Technology VenturesDRDraper Fisher Jurvetson (DFJ)

HealthtechNewark, US

Scott Cramer(Executive Officer, Director)in

BoardGlenn Reicin(Director)Richard Lin(Director)Douglas Kelly(Director)Rebecca Robertson(Director)Randy Lindholm(Director)

Co-investorsASAscension VenturesGBGBS Venture Partners Ltd.INInvesco

Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD).

HardwareHealthtechMedical DevicesMinneapolis, US

MMMartin Mayse(Founder)inSDSteve Dimmer(Founder)inDWDennis Wahr(President & CEO)inLFLisa Flaherty(Chief Strategy Officer)inSSSteve Sathre(Vice President of Finance)inSteve Paidosh(Vice President of Operations)

Co-investorsWIWindham Capital PartnersENEndeavour VisionLILightstone VenturesMOMorgenthalerQIQiming Venture PartnersRIRichard King Mellon Foundation+2 more

A healthcare company that develops and supplies medicines, including new and more affordable therapies, aiming for reliable supply of needed treatments.

BiotechHealthtechSan Francisco, US

JNJeffrey Nau(Executive Officer, Director)inMark A. Murray(Executive Officer, Director)D. Michael Ackermann(Director)

BoardWilliam J Link(Director)ABAli Behbahani(Director)in

Co-investorsFLFlying L PartnersNENew Enterprise Associates (NEA)VEVersant Venture AIV HoldingsVIVida Ventures

RayzeBio develops radiopharmaceutical therapies for cancer treatment.

BiotechHealthtechMedical DevicesSan Diego, US

KSKen Song(Executive Officer, Director)inBHBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)

BoardARAaron Royston(Director)in

Co-investorsLILifeSci Venture PartnersSASamsara BioCapitalSCScion Life SciencesSOSofinnova VenturesTCTCG CrossoverVEvenBio Partners+4 more

HealthtechDuluth, US

Anthony V. Lando(Executive Officer, Director)inTMTodd Meyer(Executive Officer)inDilip Paithanker(Executive Officer)Robert Leslie(Executive Officer)Dilip Paithankar(Executive Officer)in

BoardRebecca B. Robertson(Director)

Co-investorsACAccuitive Medical VenturesDODomain Associates

Eye-tracking and human-state platform for clinical and consumer applications.

Co-investorsRERender CapitalFLFlywheel Fund

Stablix is a preclinical-stage biotechnology company developing small-molecule medicines based on targeted deubiquitination therapeutics (TDT), using heterobifunctional molecules that recruit deubiquitinases (DUBs) to target proteins to restore protein stability and normal function.

BiotechDeep TechHealthtechNew York City, US

HCHenry Colecraft(Co-Founder & Chair of SAB)Scott Kanner(Co-Founder & Scientific Advisor)inESEddine Saiah(CEO and President)in

Co-investorsNENew Enterprise Associates (NEA)

Tempest Therapeutics is a clinical-stage biotechnology company developing in vivo CAR-T cell therapies for autoimmune and oncology indications.

BiotechHealthtechBrisbane, US

Stephen Brady(Director)inMatthew Angel(Executive Officer, Director)Nicholas Maestas(Executive Officer)inThomas W. Dubensky, Jr.(Executive Officer, Director)Thomas Woiwode(Director)Geoffrey Nichol(Director)

Co-investorsF-F-Prime CapitalLALAVLILilly Asia VenturesNENew Enterprise Associates (NEA)QUQuan CapitalRORoche Venture Fund

Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.

AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande, US

Maran Vedamanikam(CEO and Manager)Peter Qian(Co-founder & CEO)Vincent Lu(Co-founder & CTO)

Co-investorsSASamsung NextANAndreessen HorowitzWNWndrCoALAlexandriaBIBiotechnology Value FundCACasdin Capital+5 more

St.

HealthtechSt. Louis, US

SWScott Wrightstone(Executive Officer)inMaureen Oehler(Executive Officer)JPJason Pesterfield(Executive Officer, Director)inRDRyan Denney(Executive Officer)inMark Hunter(Executive Officer)inRobert Powers(Executive Officer)in

Co-investorsRCRC CapitalRERex Health VenturesSOSolas BioVenturesADAdvantage Capital PartnersPRProlog VenturesVEVensana Capital

Vividion Therapeutics develops small molecule therapeutics using a covalent-first chemoproteomics approach to identify and target previously undruggable proteins.

AI & Machine LearningBiotechDeep TechPrinceton, US

BCBen Cravatt(Scientific Founder)PBPhil Baran(Scientific Founder)JYJin-Quan Yu(Scientific Founder)Aleksandra Rizo(President and Chief Executive Officer)in

BoardJPJohn Park(Executive Officer)JCJohn Clarke(Executive Officer, Director)in

Co-investorsARARCH Venture PartnersAVAvoro Capital AdvisorsCACardinal PartnersNENextech InvestSOSoftBank Vision FundALAlexandria+4 more